Sanjib GAYEN, Shekhar ANAND, Sumanta MANNA, Sri Harsha KOMBATHULA, Sweta SONI, Akanksha SOLANKI, Sonal VARSHNEY, Puneet PAREEK

Dosimetric and Radiobiological Evaluation of Radiation-induced Pulmonary Toxicity in the Esophageal Malignancy Using VMAT

OBJECTIVE The incidence of radiation-induced pneumonitis after radiotherapy treatment of esophageal malignancy is of great concern. The study aims to evaluate the feasibility, assessing the risk of radiation pneumoni- tis (RP) with dosimetric and radiobiological outcomes treated with volumetric modulated arc therapy (VMAT) in esophageal cancer patients. METHODS Twenty patients of esophageal cancer that had received radiotherapy using VMAT in our department were retrospectively analyzed. Each of the patient’s treatment plan was analyzed with conformity index (CIRTOG), volume covering 95% isodose line (V95%), isodose line covering 95% of the target (ID95%), dose homogeneity index (DHI), low-dose volume of the organs-at-risks (OARs), normal tissue complication probability (NTCP), and risk factor (RF) of the OARs. RESULTS The prescription dose ranged from 45 to 54 Gy. The mean value of CIRTOG, V95%, ID95%, DHI, total MU, and the intensity-modulated radiation therapy ratio was 1.12±0.07, 96.58±2.43%, 95.57±2.48%, 0.92±0.03, 741.50±135.50, and 4.01±0.72, respectively. The median value of NTCP was 0.17. The observed value of RF in the lung and heart was 0.61±0.13 and 0.86±0.43, respectively. CONCLUSION The VMAT technique reduces the toxicity rate of the patient and the dosimetric as well as the radiobio- logical parameters with the quantitative analysis of dose-volume parameters such as Dmean, V20Gy, RF, and NTCP may be used to assess the probability of post-radiotherapy RP.

PDF

___

1. Madani I, de Ruyck K, Goeminne H, de Neve W, Thierens H, van Meerbeeck J. Predicting risk of radiation-induced lung injury. J Thorac Oncol 2007;2(9):864–74.
2. Hirano Y, Onozawa M, Hojo H, Motegi A, Zenda S, Hotta K, et al. Dosimetric comparison between proton beam therapy and photon radiation therapy for locally advanced esophageal squamous cell carcinoma. Radiat Oncol 2018;13(1):23.
3. Wang L, Li C, Meng X, Li C, Sun X, Shang D, et al. Dosimetric and radiobiological comparison of exter- nal beam radiotherapy using simultaneous integrated boost technique for esophageal cancer in different lo- cation. Front Oncol 2019;9:674.
4. Münch S, Aichmeier S, Hapfelmeier A, Duma MN, Oechsner M, Feith M, et al. Comparison of dosimetric parameters and toxicity in esophageal cancer patients undergoing 3D conformal radiotherapy or VMAT. Strahlenther Onkol 2016;192(10):722–9.
5. Nalbantov G, Kietselaer B, Vandecasteele K, Ober- ije C, Berbee M, Troost E, et al. Cardiac comorbidity is an independent risk factor for radiation-induced lung toxicity in lung cancer patients. Radiother Oncol 2013;109(1):100–6.
6. Warren S, Partridge M, Carrington R, Hurt C, Crosby T, Hawkins MA. Radiobiological determination of dose escalation and normal tissue toxicity in definitive chemoradiation therapy for esophageal cancer. Int J Radiat Oncol Biol Phys 2014;90(2):423–9.
7. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394–424.
8. Lin JC, Tsai JT, Chang CC, Jen YM, Li MH, Liu WH. Comparing treatment plan in all locations of esophageal cancer: Volumetric modulated arc therapy versus intensity-modulated radiotherapy. Medicine (Baltimore) 2015;94(17):e750.
9. Zhang M, Wu AJ. Radiation techniques for esophageal cancer. Chin Clin Oncol 2017;6(5):45.
10. Roeder F, Nicolay NH, Nguyen T, Saleh-Ebrahimi L, Askoxylakis V, Bostel T, et al. Intensity modulated ra- diotherapy (IMRT) with concurrent chemotherapy as definitive treatment of locally advanced esophageal cancer. Radiat Oncol 2014;9:191.
11. Tonison JJ, Fischer SG, Viehrig M, Welz S, Boeke S, Zwirner K, et al. Radiation pneumonitis after inten- sity-modulated radiotherapy for esophageal cancer: Institutional data and a systematic review. Sci Rep 2019;9(1):2255.
12. Choi KH, Kim J, Lee SW, Kang YN, Jang H. Dosimet- ric comparison between modulated arc therapy and static intensity modulated radiotherapy in thoracic esophageal cancer: A single institutional experience. Radiat Oncol J 2018;36(1):63–70.
13. Martini S, Arcadipane F, Strignano P, Spadi R, Contu V, Fiandra C, et al. Volumetric modulated arc therapy (VMAT) in the treatment of esophageal cancer pa- tients. Med Oncol 2018;35(12):150.
14. Kataria T, Govardhan HB, Gupta D, Mohanraj U, Bisht SS, Sambasivaselli R, et al. Dosimetric comparison be- tween volumetric modulated arc therapy (VMAT) vs intensity modulated radiation therapy (IMRT) for ra- diotherapy of mid esophageal carcinoma. J Cancer Res Ther 2014;10(4):871–7.
15. Safran H, Co-Chair RO, Hong TS, Hospital MG, Co- chair RO, Haddock M, et al; Radiation Therapy On- cology Group RTOG 1010. A phase III trial evaluating the addition of trastuzumab to trimodality treatment of HER2-overexpressing esophageal adenocarcinoma; 2010. Available at: https://clinicaltrials.gov/Provid- edDocs/90/NCT01196390/Prot_SAP_000.pdf. Ac- cessed Feb 22, 2022.
16. Bradley J. NRG Oncology Ecog-Acrin RTOG 1106/ Acrin 6697. Randomized phase II trial of individ- ualized adaptive radiotherapy using during-treat- ment FDG-PET/CT and modern technology in lo- cally advanced non-small cell lung cancer (NSCLC); 2016. Available at: https://clinicaltrials.gov/Provid- edDocs/28/NCT01507428/Prot_SAP_000.pdf. Ac- cessed Feb 22, 2022.
17. Feuvret L, Noël G, Mazeron JJ, Bey P. Confor- mity index: A review. Int J Radiat Oncol Biol Phys 2006;64(2):333–42.
18. Petrova D, Smickovska S, Lazarevska E. Conformity index and homogeneity index of the postoperative whole breast radiotherapy. Open Access Maced J Med Sci 2017;5(6):736–9.
19. Lee S, Cao YJ, Kim CY. Physical and radiobiological evaluation of radiotherapy treatment plan, Available at: https://www.intechopen.com/chapters/49039. Ac- cessed Sep 17, 2015.
20. Ansari S, Zope M, Yadav N. A new method for risk factor assessment of organs at risk including conform- ity index in radiotherapy treatment plan. J Radiother Pract 2021;20:144–52.
21. Beach TA, Groves AM, Williams JP, Finkelstein JN. Modeling radiation-induced lung injury: Lessons learned from whole thorax irradiation. Int J Radiat Biol 2020;96(1):129–44.
22. Williams JP, Newhauser W. Normal tissue damage: its importance, history and challenges for the future. Br J Radiol 2019;92(1093):20180048.
23. Abbas AS, Moseley D, Kassam Z, Kim SM, Cho C. Vol- umetric-modulated arc therapy for the treatment of a large planning target volume in thoracic esophageal cancer. J Appl Clin Med Phys 2013;14(3):4269.
24. Hawkins MA, Bedford JL, Warrington AP, Tait DM. Volumetric modulated arc therapy planning for distal oesophageal malignancies. Br J Radiol 2012;85(1009):44–52.
25. Yin L, Wu H, Gong J, Geng JH, Jiang F, Shi AH, et al. Volumetric-modulated arc therapy vs. c-IMRT in esophageal cancer: A treatment planning comparison. World J Gastroenterol 2012;18(37):5266–75.
26. Liang B, Yan H, Tian Y, Chen X, Yan L, Zhang T, et al. Dosiomics: Extracting 3D spatial features from dose distribution to predict incidence of radiation pneu- monitis. Front Oncol 2019;9:269.
27. Yang H, Feng C, Cai BN, Yang J, Liu HX, Ma L. Com- parison of three-dimensional conformal radiation therapy, intensity-modulated radiation therapy, and volumetric-modulated arc therapy in the treatment of cervical esophageal carcinoma. Dis Esophagus 2017;30(2):1–8